Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697447 | 1.00 | DRD3 (0.49) | DRD3DRD2OPRM1OPRK1DRD4 | |
| SCHEMBL10389820 | 1.00 | DRD3 (0.49) | DRD3DRD2OPRM1OPRK1DRD4 | |
| SCHEMBL15031376 | 1.00 | DRD3 (0.49) | DRD3DRD2OPRM1OPRK1DRD4 | |
| SCHEMBL6926415 | 0.80 | SLC6A2 (0.55) | SIGMAR1 | |
| SCHEMBL14609043 | 0.80 | SLC6A2 (0.55) | SIGMAR1 | |
| SCHEMBL15046981 | 0.79 | DRD3 (0.73) | DRD3DRD2OPRM1DRD4SIGMAR1 | |
| SCHEMBL10274630 | 0.76 | DRD2 (0.69) | DRD3DRD2DRD4SIGMAR1HTR1A | |
| SCHEMBL23923588 | 0.75 | HTR2A (0.56) | — | |
| SCHEMBL23923444 | 0.75 | HTR2A (0.56) | — | |
| SCHEMBL23940041 | 0.75 | HTR2A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790125-B | Tetrahydroisoquinoline kappa opioid antagonists | 研究三角协会 | 2022-07-05 | — | — | CN | disclosed |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3512832-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | Research Triangle Institute, International (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2773352-B1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-20020132828-A1 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2002-09-19 | — | — | US | disclosed |
| EP-1061919-A4 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RES TRIANGLE INST (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002060445-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002053533-A2 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2002-07-11 | — | — | WO | disclosed |
| EP-1061919-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | Carrol, Frank Ivy (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0506468-B1 | N-substituted 4-phenyl-piperidine opioid-antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5270328-A | Peripherally selective piperidine opioid antagonists | ELI LILLY AND COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| US-5159081-A | INTERMEDIATES OF PERIPHERALLY SELECTIVE N-CARBONYL-3,4,4-TRISUBSTITUTED PIPERIDINE OPIOID ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0506468-A1 | N-substituted 4-phenyl-piperidine opioid-antagonists | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132828-A1 | Kappa opioid receptor ligands | OPRK1, OPRD1, OPRM1 | DRD3 218/4885DRD2 256/4885OPRM1 3/4885 |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | DRD3 47/4885DRD2 20/4885OPRM1 3/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | DRD3 48/4885DRD2 20/4885OPRM1 3/4885 |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | DRD3 72/4885DRD2 94/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.